BRAF and melanoma: Likewise, vertical inhibition of MAPK signaling by combining BRAF and MEK inhibitors is now approved for BRAF‐mutant melanoma, but responses are transient and resistance to this combination is a pressing issue (Moriceau et al, 2015; Welsh et al, 2016).